

**Utilizing Real World Evidence: Focus on Multiple Myeloma
in Older Adults – Tweertorial #2**

References

Tweet 4

SEER. Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD. Accessed December 20, 2021. <https://seer.cancer.gov/statfacts/html/mulmy.html>

Zhou L, Yu Q, Wei G, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. *BMC Cancer*. 2021;21(1):606. doi:10.1186/s12885-021-08280-y

Tweet 5

Fakhri B, Fiala MA, Tuchman SA, Wildes TM. Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies. *Clin Lymphoma Myeloma Leuk*. 2018;18(3):219-224. doi:10.1016/j.clml.2018.01.005

Tweet 6

Hari P, Romanus D, Luptakova K, et al. The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. *J Geriatr Oncol*. 2018;9(2):138-144. doi:10.1016/j.jgo.2017.09.007

Tweet 7

Kaweme NM, Changwe GJ, Zhou F. Approaches and challenges in the management of multiple myeloma in the very old: future treatment prospects. Review. *Front Med (Lausanne)*. 2021;8(180):612696. doi:10.3389/fmed.2021.612696

Mohile SG, Epstein RM, Hurria A, et al. Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program. *JAMA Oncol*. 2020;6(2):196-204. doi:10.1001/jamaoncol.2019.4728

Rosko A, Giralt S, Mateos MV, Dispenzieri A. Myeloma in elderly patients: when less is more and more is more. *Am Soc Clin Oncol Educ Book*. 2017;37(37):575-585. doi:10.1200/EDBK_175171

Tweet 10

Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. *Leukemia*. 2020;34(1):224-233. doi:10.1038/s41375-019-0539-0

Tweet 11

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-83. doi:10.1016/0021-9681(87)90171-8

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5(6):649-55.

Tweet 12

Diamond E, Lahoud OB, Landau H. Managing multiple myeloma in elderly patients. *Leuk Lymphoma*. 2018;59(6):1300-1311. doi:10.1080/10428194.2017.1365859

Manapuram S, Hashmi H. Treatment of multiple myeloma in elderly patients: a review of literature and practice guidelines. *Cureus*. 2018;10(12):e3669. doi:10.7759/cureus.3669

Rosko A, Giralt S, Mateos MV, Dispenzieri A. Myeloma in elderly patients: when less is more and more is more. *Am Soc Clin Oncol Educ Book*. 2017;37(37):575-585. doi:10.1200/EDBK_175171

Tweet 13

Hungria VTM, Lee HC, Abonour R, et al. Real-world (RW) multiple myeloma (MM) patients (Pts) remain under-represented in clinical trials based on standard laboratory parameters and baseline characteristics: analysis of over 3,000 pts from the Insight MM Global, Prospective, Observational Study. *Blood*. 2019;134(Supplement_1):1887-1887. doi:10.1182/blood-2019-125749

Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. *Blood Cancer J*. 2021;11(2):40. doi:10.1038/s41408-021-00432-4

Tweet 14

Lee HC, Ailawadhi S, Gasparetto CJ, et al. Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect((R)) MM Registry. *Blood Cancer J*. 2021;11(7):134. doi:10.1038/s41408-021-00524-1

Polak TB, van Rosmalen J, Uyl-de Groot CA. Expanded access as a source of real-world data: An overview of FDA and EMA approvals. *Br J Clin Pharmacol*. 2020;86(9):1819-1826. doi:10.1111/bcp.14284

Tweet 15

Mohty M, Terpos E, Mateos MV, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. *Clin Lymphoma Myeloma Leuk.* 2018;18(10):e401-e419. doi:10.1016/j.clml.2018.06.018

Tweet 16

Lee HC, Ailawadhi S, Gasparetto CJ, et al. Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect((R)) MM Registry. *Blood Cancer J.* 2021;11(7):134. doi:10.1038/s41408-021-00524-1

Tweet 17

Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. *BMC Cancer.* 2020;20(1):1087. doi:10.1186/s12885-020-07503-y

Tweet 20

Chari A, Richardson PG, Romanus D, et al. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. *Expert Rev Hematol.* 2020;13(4):421-433. doi:10.1080/17474086.2020.1729734

Glossary

2L, second line
AIDS, acquired immunodeficiency syndrome
CCI, Charlson Comorbidity Index
Chemo, chemotherapy
CI, confidence interval
COPD, chronic obstructive pulmonary disease
CrCl, creatinine clearance
DSS, disease-specific survival
ECOG, Eastern Cooperative Oncology Group
EHR, electronic health record
HR, hazard ratio
IMiD, immunomodulatory drug
IMWG, International Myeloma Working Group
IRd, ixazomib/lenalidomide/dexamethasone
KRd, carfilzomib/lenalidomide/dexamethasone
LOT, line of therapy
MM, multiple myeloma
Mo, month
MRD, minimum residual disease
NDMM, newly diagnosed multiple myeloma
OS, overall survival
ORR, overall response rate
PFS, progression-free survival
PI, proteasome inhibitor
PS, performance status
QOL, quality of life
RCT, randomized controlled trial
Rd, lenalidomide/dexamethasone
RRMM, relapsed/refractory multiple myeloma
RWE, real-world evidence
SCT, stem cell transplant
SD, standard deviation
SEER, Surveillance, Epidemiology, and End Results program
TTNT, time to next therapy
VRd, bortezomib/lenalidomide/dexamethasone
w/, with
Wk, week